With the Professional Master’s Degree in Clinical Infectious Diseases and Antibiotic Therapeutics, you have the opportunity to expand your knowledge comfortably and without sacrificing scientific accuracy, in order to incorporate the latest advances in the approach to infectious diseases into your daily medical practice” 

master antibiotica farmaceuticos

The complex international epidemiological situation so far this century, highlights the unprecedented need to improve the process of training and development of human capital, in order to increase the competence and performance of all pharmaceutical personnel required to meet the challenges involved in controlling and dealing with biological, hospital and public health emergencies, and that guarantee the quality and safety of health care for the population in any part of the world. This has been exemplified by the deliberate release of Bacillus anthracis spores as a weapon of bioterrorism to cause pulmonary anthrax in victims who inhaled them, the emergence of West Nile virus as a pathogen in the United States, the epidemic of Severe Acute Respiratory Syndrome (SARS), the zoonotic spread of monkeypox in the United States, the threat of pandemic influenza, the Ebola epidemic in Africa, the emergence of yellow fever cases in Angola, coupled with the re-emergence of dengue and cholera, the emergence of new arboviruses in the Americas region, such as Chikingunya and more recently Zika, as well as morbidity from other endemic infectious diseases, such as HIV/AIDS, leptospirosis, tuberculosis, community-acquired pneumonia and the increase in antibiotic resistance with the development of multidrug-resistant bacteria.

The program in Clinical Infectious Diseases and Antibiotic Therapeutics is aimed at increasing the scientific education of pharmacy personnel related to research and issuing of the correct and timely treatment for infectious diseases. The program has a predominantly vocational focus, which favors the acquisition and development of knowledge and skills that will determine an improvement in the quality of pharmaceutical care of patients with infectious diseases, resulting in better morbidity and mortality rates for these pathologies in the population.  

Seize the moment and gain up-to-date knowledge on the management of infections and become a renowned pharmacist”

This Professional Master’s Degree in Clinical Infectious Diseases and Antibiotic Therapeutics contains the most complete and up-to-date scientific program on the market. The most important features include: 

  • The development of case studies presented by experts in Clinical Infectious Diseases and Antibiotic Therapeutics
  • The graphic, schematic, and practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
  • The latest developments in Clinical Infectious Diseases and Antibiotic Therapeutics
  • Practical exercises where the self-assessment process can be carried out to improve learning
  • An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course.
  • Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
  • Content that is accessible from any fixed or portable device with an Internet connection

This program is the best investment you can make in a specialization for two reasons: you will obtain a Professional Master’s Degree from the largest digital university in the world, TECH, and you will acquire the best and most up-to-date training in Clinical Infectious Diseases and Antibiotic Therapeutics”

Its teaching staff is made up of prestigious and renowned professionals with a long career in health care, teaching and research, who have worked in many countries on several continents, developing professional and teaching experience that they deliver in an extraordinary way in this program.

The methodological design is developed by a multidisciplinary team of experts in e-Learning, who integrate the latest advances in educational technology for the creation of numerous multimedia educational tools that allow the professional to face real problems in their daily clinical practice, which will allow the acquisition of knowledge and the development of skills that will impact their future professional work.

It should be noted that each of the contents generated, as well as the videos, self-tests, clinical cases and modular exams have been thoroughly reviewed, updated and integrated by the professors and the team of experts that make up the working group, in order to facilitate the learning process in an educational and phased manner to achieve the objectives of the program. 

This up-to-date program is the best on the educational landscape in infectious diseases and pharmaceuticals” 

maestria antibiotica farmaceuticos

Learn about the latest scientific evidence on infectious diseases at the pharmaceutical level"


The teaching program has been created by a group of professors and medical professionals from various medical specialties, with extensive medical, research and teaching experience in several countries in Africa, Central and South America, interested in integrating the latest and most up-to-date scientific knowledge of clinical infectious diseases and antimicrobial therapeutics, to ensure training and professional development to improve the daily clinical practice of professionals who care for patients or populations with infectious diseases.

maestria online antibiotica farmaceuticos

This Professional Master’s Degree in Clinical Infectious Diseases and Antibiotic Therapeutics contains the most complete and up-to-date scientific program on the market”

Module 1. Clinical Research in Infectious Diseases

1.1.  The Clinical Method in the Diagnostic Process of Infectious Diseases

1.1.1.  Fundamental Concepts of the Clinical Method: Stages, Principles
1.1.2.  The Clinical Method and its Usefulness in Infectology
1.1.3.  Most Common Errors in the Application of the Clinical Method

1.2.  Epidemiology in the Study of Infectious Diseases

1.2.1.  Epidemiology as a Science
1.2.2.  The Epidemiological Method
1.2.3.  Epidemiology Tools Applies in the Study of Infectious Diseases

1.3.  Clinic Epidemiology and Scientific Evidence-Based Medicine

1.3.1.  Scientific Evidence and the Clinical Experience
1.3.2.  The Importance of Evidence-Based Medicine in Diagnosis and Treatment
1.3.3.  Clinical Epidemiology as a Powerful Weapon of Medical Thinking

1.4.  Behavior of Infectious Diseases in the Population

1.4.1.  Endemic
1.4.2.  Epidemic
1.4.3.  Pandemic

1.5. Confronting Epidemic Outbreaks

1.5.1.  Diagnosis of Epidemic Outbreaks
1.5.2.  Measures for the Control of Epidemic Outbreaks

1.6.  Epidemiological Monitoring

1.6.1.  Types of Epidemiological Monitoring
1.6.2.  Designs of an Epidemiological Monitoring Systems
1.6.3.  Usefulness and Importance of Epidemiological Monitoring

1.7.  International Health Regulations

1.7.1.  Components of International Health Regulations
1.7.2.  Diseases Subject to International Sanitary Control
1.7.3.  Importance of International Health Regulations

1.8.  Mandatory Reporting Systems for Infectious Diseases

1.8.1.  Characteristics of Diseases Subject to Mandatory Reporting
1.8.2.  Role of the Doctor in Mandatory Reporting Systems for Infectious Diseases

1.9.  Vaccines

1.9.1.  Immunological Basis of Vaccination
1.9.2.  Development and Production of Vaccines
1.9.3.  Diseases Preventable with Vaccines
1.9.4.  Experiences and Results of the Vaccine System in Cuba

1.10.  Research Methodology in the Field of Health

1.10.1.  The importance of Public Health in Research Methodology as a Science
1.10.2.  Scientific Thought in Healthcare
1.10.3.  The Scientific Method
1.10.4.  Stages of Scientific Research

1.11.  Information Management and the Use of New Information and Communication Technologies (ICT)

1.11.1.  The Use of New ICT in the Management of Knowledge for Healthcare Professionals in the Professional Clinical, Teacher and Research Work
1.11.2.  Information Literacy

1.12.  Design of Research Studies for Infectious Diseases

1.12.1.  Types of Studies in Healthcare and Medical Sciences
1.12.2.  The Design of Research Applied to Infectious Diseases

1.13.  Descriptive and Inferential Statistics

1.13.1.  Summary Measures for the Different Variables in Scientific Research
1.13.2. Central Tendency Measures: Mean, Mode and Median
1.13.3.  Dispersion Measures: Variants and Standard Deviation
1.13.4.  Statistical Estimation
1.13.5.  Population and Sample
1.13.6. Tools for Inferential Statistics

1.14.  Design and Use of Databases

1.14.1.  Types of Databases
1.14.2.  Programs and Statistical Packages for the Management of Databases

1.15.  Protocol of Scientific Research

1.15.1.  Protocol Components of Scientific Research
1.15.2.  Usefulness of Protocol of Scientific Research

1.16.  Clinical Trials and Meta Analysis

1.16.1.  Types of Clinical Trials
1.16.2.  The Role of a Clinical Trial in Healthcare Research
1.16.3.  Meta Analysis: Conceptual Definitions and Their Methodological Design
1.16.4.  Application of Meta-Analyses and Their Role in the Medical Sciences

1.17.  Critical Reading of Research Results

1.17.1.  Medical Journals, Their Role in the Dissemination of Scientific Information
1.17.2.  Medical Journals of High-Impact on a Global Level in the Field of Infectology
1.17.3.  Methodological Tools for Critical Reading of Scientific Literature

1.18.  Publication of Scientific Research Results

1.18.1.  The Scientific Article
1.18.2.  Types of Scientific Articles
1.18.3.  Methodology Requirements for the Publication of Scientific Research Results
1.18.4.  The Process of Scientific Publications in Medical Journals

Module 2. Microbiological Diagnosis and Other Examinations for Infectious Diseases

2.1.  Organization, Structure and Functioning of the Microbiology Laboratory

2.1.1.  Organization and Structure of the Microbiology Laboratory
2.1.2.  Functioning of a Microbiology Laboratory

2.2.  Principles of the Use of Microbiological Examinations in Patients with Infectious Pathologies The Process of Collecting Specimens

2.2.1.  The Role of Microbiological Studies in the Diagnosis of Infectious Diseases
2.2.2.  The Microbiological Sampling Process: Preanalytical, Analytical, and Postanalytical
2.2.3.  Sampling Requirements for the Main Microbiological Studies used in Daily Clinical Practice: Blood, Urine, Stool, Sputum

2.3. Virological Studies

2.3.1.  Types of Virus and Their General Characteristics
2.3.2.  General Characteristics of Virological Studies
2.3.3.  Viral Culture
2.3.4.  Viral Genome Studies
2.3.5.  Studies of Antigens and Antibodies Against the Virus

2.4.  Bacteriological Studies

2.4.1.  Classification of Bacteria
2.4.2.  General Characteristics of Bacteriological Studies
2.4.3.  Stains for Bacterial Identification
2.4.4.  The Study of Bacterial Antigens
2.4.5. Cultivation Methods: General and Specific
2.4.6.  Bacteria That Need Special Study Methods

2.5.  Mycological Studies

2.5.1.  Classification of Fungi
2.5.2.  Main Mycological Studies

2.6.  Parasitological Studies

2.6.1.  Classification of Parasites
2.6.2.  Studies for Protozoa
2.6.3.  Studies for Helminths

2.7.  Appropriate Interpretation of Microbiological Studies

2.7.1.  The Microbiological Clinical Interrelationship for the Interpretation of Microbiological Studies

2.8.  Interpreted Reading of the Antibiogram

2.8.1.  Traditional Interpretation of the Antibiogram With Relation to the Sensitivity and Resistance to Antimicrobials
2.8.2.  Interpreted Reading of the Antibiogram: Current Paradigm

2.9.  Use of Microbial Map of an Institution

2.9.1.  What is a Microbial Map of an Institution?
2.9.2.  Clinical Application of the Microbial Map

2.10.  Biosecurity

2.10.1.  Conceptual Definitions of Biosafety
2.10.2.  Importance of Biosafety for Health Services
2.10.3. Universal Measures of Precaution
2.10.4.  Manage the Biological Waste in a Healthcare Institution

2.11.  The Clinical Laboratory in the Study of Infectious Diseases

2.11.1.  Reactants of the Acute Phase
2.11.2.  Studies of Liver Function, Internal Environment, Coagulation and Renal Function in Sepsis
2.11.3.  Study of Inflammatory Liquids in the Diagnosis of Infections
2.11.4.  Biomarkers Usefulness in Clinical Practice

2.12.  Imaging Studies for the Diagnosis of Infectious Pathology

2.12.1.  The Role of Imaging Studies in the Diagnosis of Infectious Diseases
2.12.2.  The Role of Ultrasound in the Integral Evaluation of a Patient with Sepsis

2.13.  The Role of Genetic and Immunological Studies

2.13.1.  Studies of Genetic Illnesses and Their Predisposition of Infectious Diseases
2.13.2.  Immunological Studies on Immunosuppressed Patients

2.14. Usefulness of Pathological Anatomy Studies

2.14.1.  Alterations in Cytological Studies According to the Type of the Biological Agent
2.14.2.  Necropsy and Its Importance in Infectious Mortality

2.15.  Assessment of the Severity of Infectious Diseases

2.15.1.  Prognosis Scales in the Care of Patients with Infectious Pathologies Based on Laboratory Studies and Clinical Elements
2.15.2.  SOFA Score Usefulness in the Current Day: Components of SOFA, What it Measures Usefulness in the Assessment of a Patient
2.15.3.  Main Complications in Infectious Diseases

2.16.  Worldwide Campaign Against Sepsis

2.16.1.  Emergence and Evolution
2.16.2.  Objectives
2.16.3.  Recommendations and Impact

2.17.  Bioterrorism

2.17.1.  Principle Infectious Agents Used in Bioterrorism
2.17.2.  International Regulations on the Management of Biological Samples

Module 3. The Immune System in Infections in the Immunosuppressed Host

3.1. Structure and Development of the Immune System

3.1.1. Composition and Development of the Immune System
3.1.2. Immune System Organs
3.1.3. Immune System Cells
3.1.4. Chemical Mediators in the Immune System

3.2. The Immune Response to Viral and Bacterial Infections

3.2.1. Main Cells Implicated in the Immune Response to Viruses and Bacteria
3.2.2. Main Chemical Mediators

3.3. The Immune Response to Mycotic and Parasitic Infections

3.3.1. Immune Response Against Filamentous and Yeast Fungi
3.3.2. Immune Response Against Protozoas
3.3.3. Immune Response Against Helminths

3.4. Most Common Clinical Manifestations of Immunosuppression

3.4.1. Types of Immunosuppression
3.4.2. Clinical Manifestations According to the Infectious Agent
3.4.3. Frequent Infections According to the Type of Immunosuppression
3.4.4. Common Infections in Immunosuppressed Patients According to the Organ System Affected

3.5. The Fever Syndrome in Neutropenic Patients

3.5.1. Most Common Clinical Manifestations
3.5.2. Most Diagnosed Infectious Agents
3.5.3. Most-Used Complementary Studies in the Integral Evaluation of a Neutropenic Fever Patient
3.5.4. Therapeutic Recommendations

3.6. Management of an Immunosuppressed Patient with Sepsis

3.6.1. Evaluation of Diagnosis, Prognosis and Treatment According to the Latest International Recommendations Endorsed by Scientific Evidence
3.7. Immunomodulatory and Immunosuppressive Therapy
3.7.1. Immunomodulators and Their Clinical Use
3.7.2. Immunosuppressors and Their Relation to Sepsis

Module 4. General Elements of Infectious Diseases

4.1. General and Basic Concepts of the Infectious Health-Illness Process

4.1.1. The Stages of the Infectious Process
4.1.2. The Systemic Inflammatory Response
4.1.3. Sepsis
4.1.4. Complications of Sepsis

4.2. Most Common Signs and Symptoms in Patients with Infectious Diseases

4.2.1. Local Signs and Symptoms of Sepsis
4.2.2. Systemic Signs and Symptoms of Sepsis

4.3. Main Infectious Syndromes

4.3.1. Systemic Syndromes
4.3.2. Local Syndromes

4.4. Fever of Unknown Origin (FUO)

4.4.1. Classis FUO
4.4.2. Nosocomial FUO
4.4.3. FUO in an Immunosuppressed Patient
4.4.4. FUO in HIV Infections

4.5. Fever and Rash

4.5.1. Types of Rashes
4.5.2. Main Infectious Agents Which Produce Rashes

4.6. Fever and Adenomegaly

4.6.1. Characteristics of Infectious Adenomegalies
4.6.2. Infections and Localized Adenomegalies
4.6.3. Infections and Generalized Adenomegalies

4.7. Sexually Transmitted Infections (STI)

4.7.1. Epidemiology of the STI
4.7.2. Main Agents in Sexual Transmission
4.7.3. Syndromic Approach to STIs

4.8. Septic Shock

4.8.1. Epidemiology
4.8.2. Pathophysiology
4.8.3. Clinical Manifestations and Differential Masks from the Other Types of Shock
4.8.4. Diagnosis and Evaluation of the Severity and Complications
4.8.5. Therapeutic Behavior

Module 5. Viral and Antiviral Diseases

5.1. Principles of Virology

5.1.1. Epidemiology of Viral Infections
5.1.2. Fundamental Concepts in the Study of Viruses and Their Diseases
5.1.3. Main Viruses Which Affect Humans

5.2. Hemorrhagic Viral Diseases

5.2.1. Epidemiology
5.2.2. Classification
5.2.3. African Hemorrhagic Fevers
5.2.4. South American Hemorrhagic Fevers
5.2.5. Other Hemorrhagic Fevers

5.3. Arbovirus:

5.3.1. General Concepts and Epidemiology of the Arboviruses
5.3.2. Dengue
5.3.3. Yellow Fever 
5.3.4. Chikungunya 
5.3.5. Zika
5.3.6. Other Arboviruses

5.4. Herpetic Diseases

5.4.1. Simple Herpes
5.4.2. Zoster Herpes

5.5. Viral Exanthematous Diseases

5.5.1. Rubella
5.5.2. Measles
5.5.3. Chickenpox
5.5.4. Smallpox
5.5.5. Other Exanthematous Diseases

5.6. Viral Hepatitis

5.6.1. Non-Specified Viral Infections
5.6.2. Hepatotropic Viruses
5.6.3. Acute Viral Hepatitis 
5.6.4. Chronic Viral Hepatitis

5.7. Infectious Mononucleosis

5.7.1. Epidemiology
5.7.2. Etiological Agent
5.7.3. Pathogenesis
5.7.4. Clinical Picture
5.7.5. Complications
5.7.6. Diagnosis
5.7.7. Treatment

5.8. Human Rabies

5.8.1. Epidemiology
5.8.2. Etiological Agent
5.8.3. Pathogenesis
5.8.4. Clinical Picture
5.8.5. Complications
5.8.6. Diagnosis
5.8.7. Treatment

5.9. Viral Encephalitis

5.9.1. Non-Herpetic Viral Encephalitis
5.9.2. Herpetic Viral Encephalitis
5.9.3. Slow Virus Encephalitis

5.10. Antivirals

5.10.1. General Concepts
5.10.2. Main Definitions Related to Antivirals
5.10.3. Classification
5.10.4. Mechanisms of Action

5.11. Main Antivirals for Herpes Viruses

5.11.1. Mechanisms of Action
5.11.2. Antiviral Spectrum
5.11.3. Pharmacokinetics and Pharmacodynamics
5.11.4. Dose and Presentation

5.12. Main Antivirals for Respiratory Infections

5.12.1. Mechanisms of Action
5.12.2. Antiviral Spectrum
5.12.3. Pharmacokinetics and Pharmacodynamics
5.12.4. Dose and Presentation

5.13. Main Antivirals for Hepatitis

5.13.1. Mechanisms of Action
5.13.2. Antiviral Spectrum
5.13.3. Pharmacokinetics and Pharmacodynamics
5.13.4. Dose and Presentation

Module 6. Latest Information on Coronavirus Infections

6.1. Discovery and Evolution of Coronaviruses

6.1.1. Discovery of Coronaviruses 
6.1.2. Global Trends in Coronavirus Infections

6.2. Main Microbiological characteristics and Members of the Coronavirus Family

6.2.1. General Microbiological Characteristics of Coronaviruses 
6.2.2. Viral Genome 
6.2.3. Principal Virulence Factors

6.3. Epidemiological Changes in Coronavirus Infections from its Discovery to the Present

6.3.1. Morbidity and Mortality of Coronavirus Infections from their Emergence to the Present

6.4. The Immune System and Coronavirus Infections

6.4.1. Immunological Mechanisms Involved in the Immune Response to Coronaviruses 
6.4.2. Cytokine Storm in Coronavirus Infections and Immunopathology 
6.4.3. Modulation of the Immune System in Coronavirus Infections

6.5. Pathogenesis and Pathophysiology of Coronavirus Infections

6.5.1. Pathophysiological and Pathogenic Alterations in Coronavirus Infections 
6.5.2. Clinical Implications of the Main Pathophysiological Alterations

6.6. Risk Groups and Transmission Mechanisms of Coronaviruses

6.6.1. Main Sociodemographic and Epidemiological Characteristics of Risk Groups Affected by Coronavirus 
6.6.2. Coronavirus Mechanisms of Transmission

6.7. Natural History of Coronavirus Infections

6.7.1. Stages of Coronavirus Infection

6.8. Latest Information on Microbiological Diagnosis of Coronavirus Infections

6.8.1. Sample Collection and Shipment 
6.8.2. PCR and Sequencing 
6.8.3. Serology Testing 
6.8.4. Virus Isolation

6.9. Current Biosafety Measures in Microbiology Laboratories for Coronavirus Sample Handling

6.9.1. Biosafety Measures for Coronavirus Sample Handling

6.10. Up-to-Date Management of Coronavirus Infections

6.10.1. Prevention Measures 
6.10.2. Symptomatic Treatment 
6.10.3. Antiviral and Antimicrobial Treatment in Coronavirus Infections 
6.10.4. Treatment of Severe Clinical Forms

6.11. Future Challenges in the Prevention, Diagnosis, and Treatment of Coronavirus

6.11.1. Global Challenges for the Development of Prevention, Diagnostic, and Treatment Strategies for Coronavirus Infections

Module 7. HIVIDS Infection

7.1. Epidemiology

7.1.1. Worldwide Morbidity and by Geographical Region
7.1.2. Worldwide Mortality and by Geographical Region
7.1.3. Main Vulnerable Groups

7.2. Etiopathogenesis

7.2.1. Viral Replication Cycle
7.2.2. Immune Response to HIV
7.2.3. Sanctuary Sites

7.3. Clinical Classifications of Use

7.3.1. Clinical Stages of HIV Infection
7.3.2. Clinical and Immunological Classification of HIV Infection

7.4. Clinical Manifestations According to the Stages of the Illness

7.4.1. General Clinical Manifestations
7.4.2. Clinical Manifestations By Organs and Systems

7.5. Opportunist Illnesses

7.5.1. Minor Opportunist Illnesses
7.5.2. Major Opportunist Illnesses
7.5.3. Primary Prophylaxis of Opportunistic Infections
7.5.4. Secondary Prophylaxis of Opportunistic Infections
7.5.5. Neoplasms in the Patient with HIV Infection

7.6. Diagnosis in the HIV/AIDS Infection

7.6.1. Direct HIV Screening Methods
7.6.2. Tests for Antibodies Against HIV

7.7. Antiretroviral Treatment

7.7.1. Antiretroviral Treatment Criteria
7.7.2. Main Antiretroviral Drugs
7.7.3. Monitoring of Antiretroviral Treatment
7.7.4. Antiretroviral Treatment Failure

7.8. Integral Care for a Person Living With HIV/AIDS

7.8.1. Cuban Model for Integral Care of People Living With HIV
7.8.2. Global Experiences and WHO AIDS' Leadership in HIV/AIDS Control

Module 8. Bacterial Diseases and Antimicrobials

8.1. Principles of Bacteriology

8.1.1. Fundamental Concepts of Use in Bacteriology
8.1.2. Main Gram-Positive Bacteria and their Diseases
8.1.3. Main Gram-Negative Bacteria and their Diseases

8.2. Bacterial Skin Infections

8.2.1. Folliculitis
8.2.2. Furunculosis
8.2.3. Anthrax
8.2.4. Superficial Abscesses
8.2.5. Erysipelas

8.3. Community-Acquired Pneumonia (CAP)

8.3.1. Epidemiology
8.3.2. Etiology
8.3.3. Clinical Picture
8.3.4. Diagnosis
8.3.5. Prognosis Scales
8.3.6. Treatment

8.4. TB

8.4.1. Epidemiology
8.4.2. Etiopathogenesis
8.4.3. Clinical Manifestations
8.4.4. Classification
8.4.5. Diagnosis
8.4.6. Treatment

8.5. Infections of Urinary Tract and Gynecologic Infections in Women

8.5.1. Classification
8.5.2. Etiology
8.5.3. Clinical Picture
8.5.4. Diagnosis
8.5.5. Treatment

8.6. Bacterial Meningitis

8.6.1. Immunology of the Subarachnoid Space
8.6.2. Etiology
8.6.3. Clinical Picture and Complications
8.6.4. Diagnosis
8.6.5. Treatment

8.7. Osteoarticular Infections

8.7.1. Septic Arthritis
8.7.2. Osteomyelitis
8.7.3. Infectious Myositis

8.8. Enteric and Intra-Abdominal Infections

8.8.1. Acute Gastroenteritis
8.8.2. Acute Enterocolitis
8.8.3. Primary Peritonitis
8.8.4. Secondary Peritonitis

8.9. Zoonotic

8.9.1. Concept
8.9.2. Epidemiology
8.9.3. Main Zoonotic Diseases
8.9.4. Leptospirosis

8.10. Antibacterials

8.10.1. General Concepts
8.10.2. Classification
8.10.3. Mechanisms of Action for Antimicrobials

8.11. Betalactams: Penicillin and Betalactamase Inhibitors

8.11.1. Structure of the Beta-Lactam Ring
8.11.2. Penicillins: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation
8.11.3. Beta-lactamases: Types and Action on Beta-Lactam Antibiotics
8.11.4. Main Beta-Lactamase Inhibitors
8.11.5. Uses and Therapeutic Indicatorsw
8.11.6. Cephalosporins
8.11.7. Monobactams
8.11.8. Carbapenemics

8.12. Aminoglycosides, Tetracyclines and Glycopeptides

8.12.1. Aminoglycosides: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation
8.12.2. Tetracyclines: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation
8.12.3. Glycopeptides: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation

8.13. Lincosamines, Rifamycins, Antifolates

8.13.1. Lincosamines: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation
8.13.2. Rifampicin: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation
8.13.3. Antifolates: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation

8.14. Quinolones, Macrolides and Ketolides

8.14.1. Quinolones: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation
8.14.2. Macrolides: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation
8.14.3. Ketolides: Classification, Mechanisms of Action, Antimicrobial Spectrum, Pharmacokinetics, Pharmacodynamics, Dosage and Presentation

8.15. New Antibiotics for Gram-Positive Infections (Lipopeptides and Oxazolidinones)

8.15.1. Lipopeptides
8.15.2. Oxazolidinones

Module 9. Fungal Diseases

9.1. Introduction to Mycology and Superficial Mycotic Infections

9.1.1. General Concepts Used in Mycology
9.1.2. Fundamental Characteristics of Pathogenic Fungi
9.1.3. Superficial Mycotic Infections Epidermophytosis Tinea Corporis. Tinea Capitis

9.2. Deep Mycotic Infections

9.2.1. Most Frequent Deep Mycoses
9.2.2. Main Clinical Manifestations of Deep Mycosis

9.3. Cryptococcosis

9.3.1. Epidemiology
9.3.2. Etiological Agent
9.3.3. Pathogenesis
9.3.4. Clinical Picture
9.3.5. Complications
9.3.6. Diagnosis
9.3.7. Treatment

9.4. Histoplasmosis

9.4.1. Epidemiology
9.4.2. Etiological Agent
9.4.3. Pathogenesis
9.4.4. Clinical Picture
9.4.5. Complications
9.4.6. Diagnosis
9.4.7. Treatment

9.5. Aspergillosis

9.5.1. Epidemiology
9.5.2. Etiological Agent
9.5.3. Pathogenesis
9.5.4. Clinical Picture
9.5.5. Complications
9.5.6. Diagnosis
9.5.7. Treatment

9.6. Systemic Candidiasis

9.6.1. Epidemiology
9.6.2. Etiological Agent
9.6.3. Pathogenesis
9.6.4. Clinical Picture
9.6.5. Complications
9.6.6. Diagnosis
9.6.7. Treatment

9.7. Coccidioidomycosis

9.7.1. Epidemiology
9.7.2. Etiological Agent
9.7.3. Pathogenesis
9.7.4. Clinical Picture
9.7.5. Complications
9.7.6. Diagnosis
9.7.7. Treatment

9.8. Blastomycosis

9.8.1. Epidemiology
9.8.2. Etiological Agent
9.8.3. Pathogenesis
9.8.4. Clinical Picture
9.8.5. Complications
9.8.6. Diagnosis
9.8.7. Treatment

9.9. Sporotrichosis

9.9.1. Epidemiology
9.9.2. Etiological Agent
9.9.3. Pathogenesis
9.9.4. Clinical Picture
9.9.5. Complications
9.9.6. Diagnosis
9.9.7. Treatment

Module 10. Parasitic and Tropical Diseases

10.1. Introduction to Parasitology

10.1.1. General Concepts Used in Parasitology
10.1.2. Epidemiology of the Main Parasitosis and Tropical Diseases
10.1.3. Classification of Parasites
10.1.4. Tropical Diseases and Fever Syndrome in the Tropics

10.2. Malaria

10.2.1. Epidemiology
10.2.2. Etiological Agent
10.2.3. Pathogenesis
10.2.4. Clinical Picture
10.2.5. Complications
10.2.6. Diagnosis
10.2.7. Treatment

10.3. Diseases from Intestinal Protozoa

10.3.1. Main Intestinal Protozoa
10.3.2. Diagnosis of Intestinal Protozoa
10.3.3. Amebiosis and Giardiosis

10.4. Filarial Diseases

10.4.1. Epidemiology and the Worldwide Situation
10.4.2. Clinical Syndromes
10.4.3. Main Filarial Diseases: Wuchereria Bancrofti, Brugia malayi, Brugia timori, Onchocerca volvulus, Loa loa, Mansonella Perstans, Mansonella Streptocerca y Mansonella Ozzardi

10.5. Leishmaniasis

10.5.1. Cutaneous Leishmaniasis
10.5.2. Deep Leishmaniasis

10.6. Trypanosomiasis

10.6.1. African Trypanosomiasis
10.6.2. American Trypanosomiasis

10.7. Schistosomiasis

10.7.1. Hematobium Schistosomiasis
10.7.2. Schitosomiosis Mansoni
10.7.3. Schitosomiosis Japonicum
10.7.4. Schitosomiosis Intercalatum

10.8. Intestinal Parasitism

10.8.1. Epidemiology
10.8.2. Ascaridiosis
10.8.3. Oxiuriasis
10.8.4. Hookworm Disease and Necatoriasis
10.8.5. Trichuriosis

10.9. Taeniasis Infections

10.9.1. Intestinal Tapeworms
10.9.2. Tissue Tapeworms

10.10. Antiparasitics II

10.10.1. General Concepts
10.10.2. Main Definitions Used in the Management of Antiparasitics
10.10.3. Classifications Used by Chemical Structure, Mechanism of Action or Antiparasitic Action
10.10.4. Mechanisms of Action

10.11. Antiprotozoals

10.11.1. Classification
10.11.2. Mechanisms of Action
10.11.3. Antiparasitic Spectrum
10.11.4. Pharmacokinetics and Pharmacodynamics
10.11.5. Dose and Presentation

10.12. Antiparasitic for Helminths

10.12.1. Classification
10.12.2. Mechanisms of Action
10.12.3. Antiparasitic Spectrum
10.12.4. Pharmacokinetics and Pharmacodynamics
10.12.5. Dose and Presentation

Module 11. Nosocomial Infections Associated With Healthcare and Patient Safety

11.1. Epidemiology of Nosocomial Infections

11.1.1. Operative Site Infection: Definition Epidemiology. Most Frequent Germs Therapeutic Behavior
11.1.2. Nosocomial Pneumonia and Associated Mechanical Ventilation: General Concepts Epidemiology. Risk Factors. Etiology. Diagnosis. Prevention Most-Used Antibiotics

11.2. Infection Associated With Non-tunneled Peripheral and Central Venous Catheters and Urinary Catheters

11.2.1. Epidemiology
11.2.2. Etiology
11.2.3. Risk Factors
11.2.4. Behavior for its Diagnosis and Treatment

11.3. Clostridium Difficile Infection

11.3.1. Epidemiology
11.3.2. Risk Factors
11.3.3. Clinical Manifestations
11.3.4. Diagnosis
11.3.5. Treatment

11.4. Global Vision of the Infection in Critical Patients in the ICU

11.4.1. Epidemiology
11.4.2. Risk Factors
11.4.3. Etiology
11.4.4. Prevention
11.4.5. Most-Used Antibiotics

11.5. Infections Associated With Devices Used in Medicine

11.5.1. Infections Associated with Biofilm
11.5.2. Infections From Devices Used in Orthopedics
11.5.3. Infection From Devices Used in Cardiovascular Surgery
11.5.4. Infection in Neurosurgery Devices
11.5.5. Infections of Implants and Prostheses

11.6. Universal Measures for Nosocomial Infection

11.6.1. Main Measures Internationally Recommended the Control of Nosocomial Infection

11.7. Infections Associated With Healthcare

11.7.1. Definition
11.7.2. Epidemiology
11.7.3. Etiology
11.7.4. Antimicrobials Used

Module 12. Antimicrobial Resistance

12.1. Epidemiology. From Molecular to Socioeconomic

12.1.1. Analysis of Molecular Evolution, Genetics, Clinical Manifestation, Epidemiology and Socioeconomics of the Resistance to Antibiotics
12.1.2. Mortality Due to Super Bacteria
12.1.3. Most Lethal Super Bacteria

12.2. Mechanisms of Antimicrobial Resistance

12.2.1. Genetic Mechanisms
12.2.2. Acquired Mechanisms

12.3. MRSA and GISA

12.3.1. Epidemiology
12.3.2. Resistance Mechanisms
12.3.3. Alternative Treatments

12.4. Resistant Enterobacteria

12.4.1. Epidemiology
12.4.2. Resistance Mechanisms
12.4.3. Alternative Treatments

12.5. Resistant Pneumococcus

12.5.1. Epidemiology
12.5.2. Resistance Mechanisms
12.5.3. Alternative Treatments

12.6. Viral Resistance

12.6.1. Epidemiology
12.6.2. Resistance Mechanisms
12.6.3. Alternative Treatments

12.7. Mycotic and Parasitic Resistance

12.7.1. Epidemiology
12.7.2. Resistance Mechanisms
12.7.3. Alternative Treatments

12.8. Worldwide Program for the Control of Antimicrobial Resistance and Research into New Antibiotics

12.8.1. Objectives and Action of the Worldwide Program for the Control of Antimicrobial Resistance
12.8.2. Research into New Antibiotics for Multiresistant Germs
12.8.3. Emergence of Other Forms of Treatment for Infection Control

Module 13. The Correct Use of Antimicrobials

13.1. Basic Principles in the Selection and Use of Antimicrobials

13.1.1. Elements of an Antimicrobial
13.1.2. Elements of a Germ
13.1.3. Elements of the Host

13.2. Use of Antimicrobials in Special Situations in the Host

13.2.1. Use in Kidney Failure
13.2.2. Use in Pregnancy
13.2.3. Use in Liver Failure

13.3. The Role of Policies and Rational Use of Antibiotics Programs and Their Impact on the Antimicrobial Resistance and The Cost of Medical Care

13.3.1. Situation of Programs and Policies for the Rational Use of Antibiotics
13.3.2. Impact of Programs and Policies in the Use of Antibiotics
13.3.3. Use of Clinical Practice Guides

13.4. Pharmotherapeutic Committees as Tools for the Control and Evaluation of the Use of Antibiotics

13.4.1. Structure
13.4.2. Objectives
13.4.3. Functions
13.4.4. Impact Results

13.5. Antibiotic Prophylaxis in Surgery

13.5.1. Classification of Surgical Interventions
13.5.2. Uses of Antibiotic Prophylaxis According to the Type of Surgical Intervention
13.5.3. Most Commonly Used Schemes of Antibiotic Prophylaxis in Surgery

13.6. Reasoned Therapeutics in the Use of Antibiotics

13.6.1. Stages of Reasoned Therapeutics
13.6.2. Importance of Reasoned Therapeutics

13.7. The Worldwide Experience in the Control of the Use of Antibiotics

13.7.1. Main Worldwide Experiences in the Control of the Use of Antibiotics

Module 14. The Role of Infectologists in Health Services

14.1. Infectology and its Importance in Medical Care Within Any Specialist Field

14.1.1. The Universal Nature of Infectious Pathology in Medical Specialties
14.1.2. Mastering Antibiotic Treatment

14.2. Skills and Abilities of an Infectologist

14.2.1. Skills of an Infectologist
14.2.2. Abilities of an Infectologist
14.3. The Role of Infectologists in Health Teams
14.3.1. Functions of Infectologists in Health Teams in the Different Levels of the Health System

14.4. Infectious Disease Consultation

14.4.1. Functions of an Infectologist’s Consultation
14.4.2. Pathologies to be Consulted

14.5. Scientific Update of the Infectologist’s Medical Knowledge and the Future Challenges of Infectology

14.5.1. Self-Training
14.5.2. Training and Professional Achievement
14.5.3. Future Challenges for Infectology: The Emergence of New Diseases Antimicrobial Resistance The Development of Vaccines and Antibiotics

maestria online infectología clínica y terapéutica antibiótica

Update your knowledge through this program in Clinical Infectious Diseases and Antibiotic Therapeutics”